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This  Working  Paper  has  been  prepared  as  support  for  the  European  Commission￿s 
Communication  to  the  European  Parliament,  the  Council  and  the  Economic  and  Social 
Committee. 
A detailed overview of the progress made in implementing the action plan set out in the 
Strategy is provided in the Annex. 
Actions are subdivided into four headings as follows: 
1)  Harvesting the potential (Actions 1-12):  
Actions under this heading aims at developing skills, supporting European research, 
providing  a  strong  European  intellectual  property  system,  facilitating  access  to 
capital, networking all the various stakeholders working in biotechnology in Europe 
and increasing the proactive role of the public authorities.  
2)  A key element for responsible policy: governing life sciences and biotechnology 
(Actions 13-23):  
These actions includes dialogue among stakeholders, ethical and social implications, 
consumers￿ right to choose and the legislative framework.  
3)  Europe in the world ￿ responding to global challenges (Actions 24-28):  
These  actions  highlight  Europe￿s  role  in  developing  international  guidelines  and 
indicate the areas where Europe can support the developing world in its efforts.  
4)  Implementation  and  coherence  across  policies,  sectors  and  stakeholders 
(Actions 29 and 30):  
This final group of actions focuses on the role of the Commission in evaluating and 
further developing the Europe￿s biotechnology policy in the coming years. 
In the current early phase of implementation of the action plan, this overview focuses on 
action  undertaken  by  the  Commission,  and  only  provides  occasional  reference  to  other 
stakeholder activities.   3    
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 N°  Action/ 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
1  The Commission will, together with Member States,
￿ ￿ ￿ ￿ identify the education needs in life sciences
within the 'Ten-year objectives for learning in the
knowledge society' and strengthen a broad
education and understanding of life sciences, and
develop and train a skilled workforce in life
sciences by issuing recommendations for curricula
and teacher training. Community support can be
provided under the Comenius and Erasmus
programs.
￿  ￿  ￿  ￿ A call for proposals under the second phase of 
the Leonardo Program (for vocational training) has 
been launched (2003-2004). Life Sciences and 
Biotechnology can be proposed specific priorities 
themes in the call under various actions
￿  ￿  ￿  ￿ A detailed work program on the future 
objectives of education and training systems was 
adopted on 14.2.2002. Work had already started on 3 
priority objectives: 'basic skills', ICT and 'Math, 
Sciences and Technologies'
￿ ￿ ￿ ￿ While the Commission support this action through 
its various education programs, recommendations for 
developments of curricula are strictly competence 
of Member States
Members States, 
Commission, 
private sector
￿ promote continuing education and refresh the
current competence of the scientific workforce, as
set out in its communication on the European area
of lifelong learning. Community support can be
provided under the Leonardo program  
￿  ￿  ￿  ￿ The Communication on 'Making a European Area 
of Lifelong Learning a Reality' includes key concrete 
actions to provide people of all ages with equal and 
open access to high-quality learning opportunities. An 
interim report on progress towards implementing the 
lifelong framework will be presented by to the 2003 
Spring European Council.
￿ support discussion for specialist scientists, with
the objective of stimulating an exchange across
disciplines. Community support can be provided
under the Erasmus program
￿  ￿  ￿  ￿ A number of  'Thematic Network Projects' in the 
specific area of Biotechnology consisting of university 
cooperation projects have been supported under the 
Socrates-Erasmus program (for education)
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
Investing in people 
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2 (a)  ￿  ￿  ￿  ￿ the Commission will explore with Member 
States the opportunity and best way to establish 
efficient methods to match a skilled workforce 
with job opportunities, involving effective 
communication of open positions, collaboration with 
established companies and a labour force aware of 
available employment options.
￿ ￿ ￿ ￿       high level task force was established in 2001 to 
address the challenges of skills and mobility on 
European labour markets.  
￿  ￿  ￿  ￿ On the basis of the task force's report,       in 
February 2002 the Commission adopted an Action 
Plan for Skills and Mobility, endorsed by the 
Barcelona Summit in March 2002. 24 separate actions 
were identified with many linked directly to investing in 
people and ensuring skills matching. Action 2 seeks to 
promote  maths, science and technology skills, action 
4 seeks closer links between education, industry and 
careers guidance. Actions 23 and 24 explicitly address 
the issue of a one stop mobility and 
information/qualifications website and the existing 
EURES website on the classification of professions.
￿  ￿  ￿  ￿ The Commission works together with Member 
States via the European Employment Strategy to 
improve and enhance employment, seeking both more 
and better jobs. As part of this process, Member States 
prepare and present National Action Plans (NAPs) for 
employment on the basis of guidelines agreed at the 
beginning of the year. Within the guidelines for 2002, 
and thus in all NAPs, is action on matching jobs with 
skills and combating bottlenecks.
Member States, 
Commission
2 (b)  ￿ The Commission will explore with Member States 
possible measures to attract and retain scientists 
and avoid brain drain. 
￿ ￿ ￿ ￿       Under the specific program "Structuring the 
European Research Area"(2002-2006), the 
Commission will offer 
￿ increased opportunities for mobility across Europe 
and implement actions to counteract the brain drain. 
Researchers from third countries will be able to 
participate with a view to reinforce the skilled workforce 
in Europe
￿ ￿ ￿ ￿ seed grants to allow researchers to return to their 
own countries and establish research capacities. 
￿  ￿  ￿  ￿ The Sixth Framework Program for Research 
(FP6) expands the training through research program 
and offers new tools well adapted to the present 
situation. In particular there will be new possibilities 
offered for exchanges with Third Countries and for 
the establishment of new European research teams. 
Member States, 
Commission
2003
onwards
2003
onwards
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 N° Action/ 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
 
3 
2002-06 
￿ The Commission will enhance support for 
life sciences and biotechnology research, 
technological development, demonstration 
and training activities under the Sixth 
Framework Program 2002-2006 aimed at 
        ￿ ￿ ￿ ￿ contributing towards the creation of the 
European Research Area.
  ￿    ￿    ￿    ￿ supporting Biotechnology research 
under 5 thematic priorities
  ￿    ￿    ￿    ￿ encouraging SME participation, 
international cooperation and mobility and 
training of researchers. 
  ￿    ￿    ￿    ￿ to facilitate the objectives of Europe-
wide collaborations, attaining critical mass 
and simplification of administrative 
procedures.
￿  ￿  ￿  ￿ The Sixth Framework Program (FP6) 2002-
2006 was adopted by Council and the European 
Parliament on 3 June 2002 (Decision No 
1513/2002/EC - OJ L232).  
￿  ￿  ￿  ￿ The 5 specific programs have been 
considered by European Parliament, and they 
were adopted by the  Council on 30 September 
2002 (Decisions 2002/834/835/836EC and 
837/838/Euratom -OJL294)
￿ ￿ ￿ ￿ The Rules of Participation to implement 
FP6 were adopted by Parliament and Council on 
5 November 2002
￿  ￿  ￿  ￿ a call for expressions of interest was 
launched in March 2002 with a deadline of 
7June. Some 11,000 expressions of interest 
were received
￿ ￿ ￿ ￿ the Commission issued calls for proposals 
on 17 December 2002, with a  closing date in 
March-April 2003. 
Members States, 
EIF, Commission
￿ The Commission and the Member States 
and in collaboration with the European 
Investment Fund (EIF), will develop a 
competitive bioinformatics infrastructure 
in support of biotechnology research and 
focus support for the development of research 
in computational biology and bio-medical 
informatics. 
￿  ￿  ￿  ￿ Several projects supporting bioinformatics 
are funded under FP5, the largest being 
TEMBLOR, a 3-year project with an EU 
contribution of ￿19,4m to 25 participants, 
coordinated by the European Bioinformatics 
Institute (EMBL-EBI)
￿ ￿ ￿ ￿ The Commission and the EIB/EIF have 
established a working group to investigate the 
issue of the financing of infrastructure, including 
bioinformatic infrastructures (see action 6a)
￿ ￿ ￿ ￿ The first two calls from FP6 in the area of 
fundamental genomics will include 
￿  ￿  ￿  ￿ developing methods and resource in 
bioinformatics to focus on the annotation of 
human and other genomes
￿ ￿ ￿ ￿ Bioinformatics and genomics grid for EU 
research
￿  ￿  ￿  ￿ development of an integrated software 
platform to tackle genomic sequence-structure-
function relationships
￿ ￿ ￿ ￿ proposals for dealing with in silico prediction of 
gene function and for the simulation of complex 
regulatory framework
2002-06
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State of implementation of action plan 
(1)
4  To enhance the supply of specific management and
legal skills:
￿ ￿ ￿ ￿ Member States and national biotechnology
associations should examine the opportunity of
creating self-sustained networks of biotechnology
company managers at the national level.
￿ ￿ ￿ ￿ Member States and the Commission should
promote collaboration between law schools, law
firms and companies for the development of
specific legal competence needed by
biotechnology companies.
￿  ￿  ￿  ￿ In 2003 the Commission, together with Member 
States and national industry associations, will explore  
the opportunities and best ways of providing this 
expertise at national level .
￿ ￿ ￿ ￿ Young biotechnology companies often need better 
access to entrepreneurial/management skills and 
specific legal expertise (e.g. IPR/licensing contracts). 
Creation of self-sustained networks of biotechnology 
company managers, possibly including the involvement 
of specialized law schools/firms for the development of 
specific legal competence, might help to improve 
access to expertise.
Member States, 
academia, 
professional 
associations, 
Commission
Management and legal services
2003
onwards
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State of implementation of action plan 
(1)
5 (a) To finalize a strong, harmonized and affordable 
European intellectual property protection system by
￿  ￿  ￿  ￿ Member States urgently transposing into 
national laws the Directive 98/44/EC on the Legal 
Protection of Biotechnological Inventions.
￿ ￿ ￿ ￿ To date, six Member States have transposed the
Directive (DK, FIN, IRL, UK, GR, ES)
￿ ￿ ￿ ￿ The Commission has launched the second stage
of formal infringement proceedings against Members
States which have not yet transposed the Directive. In
the light of the recent ruling of the Court of Justice
confirming the compatibility of the Directive with
various legal principles and internation obligations, the
Commission will consider what action is appropriate to
ensure a full and speedy transposal of the Directive
into national law, where this has not already been
achieved.
￿  ￿  ￿  ￿ As provided for by Article 16(b) of Directive 
98/44/EC, on 14 January 2002, the Commission has 
adopted a report assessing of the implications for 
basic genetic engineering research of failure to 
publish, or late publication of, papers on subjects 
which could be patentable as required under Article 
16(b) of Directive 98/44/EC on the legal protection of 
biotechnological inventions (COM(2002)2 Final)
￿  ￿  ￿  ￿ As provided for by Article 16(c) of Directive 
98/44/EC, on 7 October 2002, the Commission has 
adopted a report on the development and 
implications of patent law in the field of 
biotechnology and genetic engineering (COM(2002) 
545 Final)
Member States, 
Council, 
Commission
￿  ￿  ￿  ￿ The Commission has already set up a group of 
experts in economics, law and natural sciences to 
examine controversial issues linked to biotechnology 
patent and to help it to prepare future annual reports. 
The two topics to be studied in 2003 will be i) the 
scope to be given to patents related to sequences or 
partial sequences of genes isolated form the human 
body, and ii) the potential patenting of human stem 
cells and cell lines obtained from them. These topics 
will be discussed by the Group in March and May 
2003 respectively. Reports from those discussion will 
be made available at the same time as the 2003 
Commission annual monitoring  report.
Exploitation of intellectual property
2002
onwards
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(1)
 N°  Action/ 
Timeframe
Description of the Action State of play Comments/
Further follow-up
Implementer
5 (b) ￿  ￿  ￿  ￿ Council adopting the Community Patent 
Regulation. 
￿  ￿  ￿  ￿ On 1.8.2000 the Commission adopted a Proposal 
for a Council Regulation on Community Patent 
(COM(2000) 412 Final). 
￿  ￿  ￿  ￿ The European Parliament delivered its opinion on 
10.4.2002. 
￿  ￿  ￿  ￿ The Council reached a political agreement on 
3.3.2003.
￿  ￿  ￿  ￿ The political agreement reached on 3 March 2003 
enables the work on the details of the Regulation to continue 
efficiently in the Council with a view to its adoption as soon 
as possible,
Member States, 
Council, 
Commission
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
5 (c) ￿ ￿ ￿ ￿ Member States and the Commission clarifying
rules on ownership of intellectual property
stemming from public research and monitoring the
effect of implementation of patent legislation on
research and innovation.
￿  ￿  ￿  ￿ The Commission has contracted out a study in 
January 2002 which will provide a detailed comparative 
analysis of the Intellectual Property Research (IPR) 
rules applicable to publicly-funded research, their 
evolution and their effects, in the 15 EU Member 
States, in 2 adhesion countries, as well as in the US 
and Japan. The final report is expected in spring 
2003.The study will mainly focus on legislative aspects 
and aim at the identification of recommendations which 
could improve the coherence of the IPR regimes 
applicable to publicly funded research in the European 
Union
￿ ￿ ￿ ￿ In parallel, an expert group of technology transfer 
and legal specialists has been set up. This group 
primarily aims at identifying good practices and 
recommendations at user level.
￿  ￿  ￿  ￿ This action will in particular benefit the 
biotechnology sector, since the majority of technology 
transfer activity and licensing from the public research 
sector is in this area. The analysis of the study and 
expert group recommendations will allow to identify 
problems and good practices, and to define possible 
actions by the Commission and/or Member States 
aimed at improving the efficiency and coherence of 
these rules in the EU, taking into account the 
international context.
Member States, 
Council, 
Commission
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
 
5 (d) ￿  ￿  ￿  ￿ encouraging awareness training in the strategic 
use of IPR during the entire research and innovation 
process and raising awareness among academics 
of the commercial potential of their research, 
encouraging entrepreneurship and movement 
between academia and companies.
Various initiatives have recently been launched at
regional, national and Commission level, such as 
￿ ￿ ￿ ￿ the PROTON network of technology transfer
licensing offices in Europe aimed at increasing
professionalism of technology transfer activities in
Europe.
￿  ￿  ￿  ￿ Training and awareness initiatives will be 
supported through the Sixth Framework Program 
(FP6), both through specific support actions of the 
thematic priorities focusing on biotechnology and life 
sciences, as well as through measures supported 
through the “research and innovation” area of the 
specific program on “structuring the European 
Research Area”. 
￿  ￿  ￿  ￿ Movement between academia and companies is 
strongly encouraged through the mobility grants of 
FP6, for which the budget has been doubled in 
comparison to the last framework program.
Member States, 
Council, 
Commission
￿ ￿ ￿ ￿ the IPR-Helpdesk which provides a helpdesk on IP
issues for mainly for participants of the EU RTD
framework program or the “EuroBioBizz” training
activity that helps potential biotech entrepreneurs in
writing professional business plans . 
￿ ￿ ￿ ￿ On a broader level, the Gate2Growth Initiative
provides tools and networks for access to finance and
better exploitation of knowledge.
￿  ￿  ￿  ￿ The websites of the newly established IPR-
Helpdesk and Gate2Growth Initiatives may serve as 
an information platform for communicating the various 
national and regional initiatives and providing 
information on and links to training and awareness 
activities. 
￿  ￿  ￿  ￿ The next edition in November 2003 of the bi-
annual PATINNOVA conference in Luxembourg could 
also be used as a communication platform for 
initiatives in the biotech sector.
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
5 (e) ￿  ￿  ￿  ￿ taking steps to promote international 
dialogue and co-operation with a view to work 
towards a level playing field with industrialized 
countries in patent protection on biotechnology 
inventions, ensuring an effective level of protection 
for innovation in this field.
￿  ￿  ￿  ￿ Harmonization of intellectual property law in 
industrialized countries is currently being discussed at 
the level of the World International Property 
Organization (WIPO) in its Standing Committee on 
Patent Law (SCP). A number of very important issues 
are being discussed, such as the patentability criteria, 
the  patentable subject matter and the grace period.
￿  ￿  ￿  ￿ The Commission prepared a working document 
on these issues which was discussed with the Member 
States during the General Assemblies of WIPO (23 
September-1 October 2002) which decided that works 
dedicated to the PCT reform should be pursued.
￿  ￿  ￿  ￿ Discussion on Substantive Patent Law Treaty 
(SPLT) will continue under the auspices of WIPO 
Member States, 
Council, 
Commission
￿  ￿  ￿  ￿ In parallel, the reform of the Patent Cooperation 
Treaty (PTC) has been undertaken in order to 
streamline and to simplify the PCT procedure and to 
avoid duplication of works. The real purpose of this 
exercise is to solve the increasing workload of the 
Patent Offices.
Both exercises should allow to create a more user 
friendly system for the applicants and to reduce the 
discrepancies on patent law among the Parties of 
WIPO
￿  ￿  ￿  ￿  The "grace period" is a particular important 
issue regarding research co-operation on an 
international level. For this reason, the Commission 
has organized two workshops on this topic
￿  ￿  ￿  ￿ The “grace period” discussed during the 
workshops could serve as a basis for defining a 
common European standpoint at the current SPLT 
negotiations
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
6 (a)  The Commission should, together with the European 
Investment Bank (EIB) and the European Investment 
Fund (EIF), strengthen the capital base for the 
biotechnology industry, by:
￿  ￿  ￿  ￿ seeking to stimulate investments in research and 
technological innovation via complementary 
financing on the basis of the co-operation agreement 
signed in June 2001 between the Commission and 
the EIB group.
￿ Three workings groups chaired by the 
Commission, European Investment Bank (EIB) and 
European Investment Fund (EIF) have been set up to 
investigate the issues of  
￿  ￿  ￿  ￿ support R&D financing via direct financing and 
guarantee mechanisms; 
￿ ￿ ￿ ￿    financing of infrastructures; 
￿ ￿ ￿ ￿ availability of risk capital and support to 
incubators.
￿ ￿ ￿ ￿ The financing instruments of the EIB, including 
information on recent projects and case studies, will be 
actively promoted by the Commission and EIB, e.g., 
through their websites and through information 
contained in the “INFO PACK” to the new framework 
program. Concrete results and recommendations for 
further collaboration and the development of new 
financing instruments is expected by the launch of 
Sixth Framework Program.  In addition, the 
Commission will target appropriate industrial partners 
who are currently project participants of the framework 
program to evaluate the interest for and potential of 
complementary financing instruments of the EIB. 
EIB group, 
Commission
￿ Since June 2001, the EIB has made R&D the 
centerpiece of its ongoing "Innovation 2000 
Initiative" (i2i), one of the two pillars of the co-
operation agreement between the Commission and 
EIB with the Framework Program for Research and 
Technological Development (FPRTD). EIB has 
substantially increased its financing of research and 
innovation. From 1990 to 1999, EIB had loaned 245 
million ￿ . From 2000 to present, under i2i, EIB 
approved 9.1 billion ￿ in loans, of which 4.2 billion for 
research.
 ￿    ￿    ￿    ￿  R&D will remain a key objective for EIB 
lending in the years to come. A particular focus will be 
on supporting private R&D by SMEs, large companies 
as well as "mid-caps" and on fine-tuning EIB financial 
instruments to each sector. The EIF will continue to 
support universities and research centers in the 
creation of investment funds and new vehicles. 
Furthermore, EIF is currently setting up a consultancy 
operation. In doing so, EIF aims to bridge the gap 
between research and product development.
Capital base
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
6 (b) ￿  ￿  ￿  ￿ seeking to stimulate investments in business 
incubators through the EIF Start Up Facility
￿ ￿ ￿ ￿ In the year 2001, the EIF has done major
investments in biotech VC funds linked largely to
regional clusters and bioincubators, such as
“Heidelberg Innovation” in Germany, “BioAm” in 
France and “Symbion” in Denmark. These
commitments have been done through EIB funding,
which represent 90% of the EIF VC resources.
Altogether, 8 funds have been created that devote
100% of their capital to the biotech sector. Through 55
general funds, 223 biotech start-ups have been
financed. Another ￿49 million were invested in smaller
and regional start-up funds through the ETF start-up
facility. 
￿  ￿  ￿  ￿ Through the multi-annual action plan (MAP), 
￿317 million of financing will be available for the ETF 
start-up facility for the 2001-2005 period, with a focus 
on incubators and seed-capital funds. 
￿ A working group comprising venture capital fund 
managers, banks, industry, bio-cluster managers, 
research organizations and research and industry 
ministries could be established to investigate how other 
regional actors could be involved in public-private 
partnerships, together with the EIF, to improve early 
stage financing for biotech start-ups. 
￿  ￿  ￿  ￿ Increase of the EIB VC funds will be 
investigated.
EIB group, 
Commission
6 (c) ￿  ￿  ￿  ￿ studying measures to support technology 
transfer mechanisms, such as financing of patent 
pools or other methods for patent exploitation.
￿  ￿  ￿  ￿ A specific working group will be set up at the 
beginning of 2003, initiated through the Biotech and 
Finance Forum, comprising the PROTON network of 
European technology transfer offices and researchers, 
industry, financiers from the biotech sector to identify 
best practices in financing of technology transfer 
related to biotechnology.
The objective of this group is to give policy 
recommendations for Member States, regional 
authorities and public research organization on how to 
best support the process of technology transfer. Best 
practices such as successful examples of public-
private partnerships involving universities and regional 
financiers (banks, industry, etc.), co-operation of 
universities with private technology transfer firms or 
other novel examples of technology transfer initiatives 
should be identified and widely promoted. 
￿  ￿  ￿  ￿ The US experience has shown that professional 
technology transfer structures are a major success 
factor for the exploitation of publicly funded research 
through licensing and start-up generation. Professional 
structures do not exist widely across Europe at the 
desired level, although some member states have 
recently initiated actions to support and increase 
technology transfer from the public sector, e.g. by 
supporting patent applications from the public research 
sector.
Europe therefore needs to increase its support for the 
establishments of new or the professionalisation of 
existing structures, through regional or national 
initiatives, with sufficient private involvement and 
financing to guarantee a market driven approach.
EIB group, 
Commission
2002
onwards
2002
onwards
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State of implementation of action plan 
(1)
  
6 (d) ￿  ￿  ￿  ￿ studying measures to encourage commercial 
financing of companies based on a medium-term 
investment perspective.
￿ ￿ ￿ ￿ On recommendation of the Biotech and Finance
Forum (BFF - see action 7 for further details), the
Commission set up a small ad-hoc working group
comprising members of the BFF board, experts from
biotech focused large VC companies and the EIB/EIF
to investigate new financing instruments. A report was
delivered in November 2002, recommending a stronger
EIB/EIF/EC support for late stage investments and
consolidation funds to support the further growth of the
EU biotechnology industry.
￿  ￿  ￿  ￿ The EIB and EIF, with the support of experts from 
the BFF group, will examine ways of implementing the 
recommendations of the working group, in particular 
raising support for later stage investments and 
consolidation funds, by spring 2003.
EIB group, 
Commission
￿ ￿ ￿ ￿ The Commission finalized the terms of reference
for a “Biotech finance study” that should investigate
financing gaps in the various Member States and other
countries. 
￿  ￿  ￿  ￿ The Biotech Finance Study will examine in detail, 
on a country-by-country basis, the respective ease of 
access to capital that biotechnology companies have: 
(a) at each stage of finance, (b) take-up/usage of 
EIB/EIF finance, and (c) in general, relative to other 
innovative companies.
7 ￿  ￿  ￿  ￿ To strengthen the work of the Biotechnology 
and Finance Forum by the inclusion of relevant 
major stakeholders to provide advice into policy 
development in the field of capital supply. 
￿ ￿ ￿ ￿ The Biotechnology and Finance Forum (BFF)
was set-up as a joint initiative between the European
Commission and the European Association of Security
Dealers in 1997 to promote networking between
researchers, entrepreneurs, industry and finance and
support financing of biotech ventures. The BFF has
organized 4 conferences in recent years, which
attracted on average around 300 participants. A total of
200 investment presentations by biotech companies
have been done and numerous important financing
deals have emerged from these meetings. On
22.4.2002, the first meeting of the new BFF advisory
board took place. This board includes all relevant
biotech stakeholders in Europe, such as EuropaBio,
the European Federation of Biotechnology (EFB), the
European Venture Capital Organization (EVCA), the
EIB, EIF and Eureka. Representatives of major bio-
clusters, venture capital firms, consultants, etc. in the
biotech sector are also present.
￿ ￿ ￿ ￿ An ad-hoc working group will be set up at 
beginning 2003 to look into financing of professional 
technology transfer and medium term financing 
mechanisms (see action 6c). 
￿ ￿ ￿ ￿ The BFF board will meet in early 2003 to review the 
activities and to set priorities for working groups and 
other activities for 2003. 
￿ ￿ ￿ ￿ A BFF conference is planned for February 2003.
Commission
2002
onwards
2002
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
8 (a) ￿ ￿ ￿ ￿ The Commission will support creation of a
commercial biotechnology web portal for
Europe that will help free access to information and
networking available Internet platforms. 
￿ ￿ ￿ ￿ Following the launch of a call for proposals, five
responses have been received and they are currently
being evaluated 
￿ ￿ ￿ ￿ The web site(s) would be expected to be fully
operational by the end of 2003. 
Commission
8 (b) ￿  ￿  ￿  ￿ the Commission will develop its newly created 
Commission web site to provide a broad entry 
platform into the Commission’s work on 
biotechnology.
￿  ￿  ￿  ￿ A thematic portal on Europa website under 
‘Biotechnology’ is currently available. 
￿  ￿  ￿  ￿ Further developments of the structure and 
contents of this site are currently under evaluation. The 
web site is expected to be developed and operational 
by end of 2003
Commission
9 (a) ￿  ￿  ￿  ￿ Member States, their regions, the Commission 
and the EIB will support stronger interregional co-
operation, e.g. through a network of biotechnology 
regions. Crossborder and interregional co-operation 
can receive funding from the Interreg programs 
(notably Interreg IIIB and IIIC).
￿  ￿  ￿  ￿ While the Commission through its regional policy 
supports this action, the procedures of selection of 
concrete projects are matter for the Member States.
￿  ￿  ￿  ￿ Stronger interregional co-operation in the life 
sciences and biotechnology area is developing in a 
number of European regions. These activities, such as 
interregional networks, can be considered eligible for 
financing under the INTERREG III initiative. The 
INTERREG III programs (strands A, B and C) are now 
operational in all Member States. In particular, the 
INTERREG III C program launched its first call for 
proposals of projects on 10 October 2002, which 
closed on 10 January 2003. All relevant information 
about this program can be found on the following 
website: www.interreg3c.net
Member States, 
regions, EIB, 
Commission
￿  ￿  ￿  ￿ The Commission, through the 5th Research 
Framework Program, has recently funded the “Baltic 
Biotech Forum”, an accompanying measures out of 
which the SCAN BALT initiative has evolved, which 
aims at networking biotechnology activities and 
clusters around the Baltic Sea. The Baltic Sea region 
has also recently received support for transnational 
collaboration from the Interreg III program
Networks in Europe
2002-03
2002-03
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan 
(1)
9 (b) ￿  ￿  ￿  ￿ Member States, their regions, the Commission 
and the EIB will support networks of 
biotechnology clusters. In addition, the 
Commission will organize a European competition 
between Biotechnology Innovation clusters, to 
highlight their capability to develop a cluster with a 
focus of excellence in a specific scientific field.
￿ ￿ ￿ ￿ Networks of biotechnology clusters have been
and are being developed in Europe. Examples are the
BioValley network of clusters covering Rhone-Alp
(FR), Freiburg (DE) and Basel (CH), as well as the
Medicon Valley covering both Danish and Swedish
regions around Copenhagen and Lund. 
￿ ￿ ￿ ￿ The Commission has recently funded the “Baltic 
Biotech Forum” (see action 9a)
￿  ￿  ￿  ￿ Networking of biotechnology clusters can be 
actively supported within the 6th Framework Program 
through specific support actions in the life science 
thematic priorities as well as through measures 
financed through the specific program on “structuring 
the European Research Area”. It is planned to 
organize a workshop early 2003 that will bring 
together managers of biotech clusters to discuss 
possible new networking initiatives and highlight 
funding opportunities of the framework program and 
other sources, such as structural funds or those of the 
EIB/EIF. This workshop will also discuss the needs of 
biotech clusters to develop specific scientific, 
management and other competencies throughout 
Europe. This reflection could serve as a basis for 
developing specific targeted calls within the 6th 
Framework Program.
Member States, 
regions, EIB, 
Commission
10 (a) ￿  ￿  ￿  ￿ the Commission will establish a 
competitiveness monitoring function and a 
contact network with Member States ministries 
with responsibility for competitiveness in 
biotechnology. Monitoring should include impact 
on European competitiveness of legislation and 
policy measures. 
￿  ￿  ￿  ￿ The contact network has been established with 
12 out of 15 Member States participating. It met for the 
first time in July 2002. A further meeting is planned for 
the next months
￿ ￿ ￿ ￿ The network has so far positively contributed to the 
developments of national positions
10 (b) ￿  ￿  ￿  ￿ the Commission will establish a 
Competitiveness in Biotechnology advisory 
group with industry and academia to assist in 
identification of issues affecting European 
competitiveness. The Group will provide input into 
the Commission’s regular reports on Life Sciences 
and Biotechnology.
￿  ￿  ￿  ￿ Reflections on terms of reference and composition 
of the group have started. 
￿  ￿  ￿  ￿ A first meeting of the group should be envisaged 
for May 2003
A proactive role for public authorities
Member States, 
Commission
2003-06
2002
2002
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State of implementation of action plan 
(1)
11 Transparency in the administrative process:
￿  ￿  ￿  ￿ The Commission and Member States should aid 
applicants, especially from start-up companies and 
SME’s, requesting approval through the regulatory 
process. 
￿  ￿  ￿  ￿ the Commission should issue a guide to 
Community regulation for users and for 
entrepreneurs who have limited staff and expertise in 
the regulatory and legal fields.
Such a guide should also benefit non-EU (e.g. 
developing world) applicants and the general public.
￿  ￿  ￿  ￿ The Commission already provides various but 
spread and selective information on Community 
biotechnology legislation/its management, such as
￿  ￿  ￿  ￿ the information it provides about the various 
"dossiers" concerning applications for EU 
authorization of GMOs; 
￿  ￿  ￿  ￿ web-site on pharmaceutical legislation;
￿  ￿  ￿  ￿ SMEs User Guide on biotechnology
￿  ￿  ￿  ￿ The main aims of this action are to facilitate 
comprehensive information on biotechnology-relevant 
legislation, and ultimately, long-term investment in 
biotechnology that is in compliance with the developing 
regulatory framework in the EU, and public 
understanding of the development of that framework.
The new Guide will be drafted in 2003/2004, when the 
new legislative framework will be in place, and will be 
the main instrument for access to information. It will be 
published on the Commission's biotechnology web-
pages and regularly updated.
Member States, 
Commission
12 ￿  ￿  ￿  ￿ In collaboration with the involved actors, the  
Commission will benchmark good practices in 
clustering biotech companies and in the work of 
business incubators and disseminate results.
￿  ￿  ￿  ￿ The Commission will establish with Member 
States a program for benchmarking relevant 
elements of biotechnology policies, in addition to 
existing benchmarking structures.
￿  ￿  ￿  ￿  a benchmarking program involving interested 
Member States was endorsed by the Council and 
included in the road map adopted on 26 November.
￿ ￿ ￿ ￿ the possible contents of the benchmarking program
will be discussed in early 2003 within the contact
network with Member States ministries with
responsibility for competitiveness in biotechnology (see
action 10a) on the basis of the roadmap.
Commission
2003
onwards
2003
onwards
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13 (a) ￿  ￿  ￿  ￿ The Commission will propose a 
framework for a process of dialogue and 
follow-up with stakeholders as a result 
of the European strategy for life sciences 
and biotechnology. The framework will 
notably include a broadly based 
Stakeholders’ Forum. 
￿ ￿ ￿ ￿ The preparation of the Stakeholders' 
Forum is underway and it is planned to be
set up in 2003, when new key legislation is
expected to be in place and
Council/European Parliament will have
given their response to the Commission’s
proposed strategy.
￿  ￿  ￿  ￿ The Stakeholders' Forum will be 
composed of representatives of all main 
stakeholders and societal groups 
(consumers, environmentalists, industry, 
trade union, academia, ethicists, etc.) and 
institutions (EP/national parliaments, 
regions…). Candidate countries and Third 
countries will also be invited to participate. 
While the scope of its debate should be 
broad (regulatory framework and underlying 
principles, role of science, main ethical 
issues), the Forum should not duplicate, but 
complement discussions in other, mostly 
more specialist or expert fora.
Member States, 
industry, 
academia, civil 
society, EFSA, 
EMEA, 
Commission
13 (b) ￿  ￿  ￿  ￿ the Commission will promote 
awareness of key scientific paradigms 
underlying regulatory oversight, within 
their respective fields, the European 
Food Safety Authority and the 
European Agency for the Evaluation of 
the Medicinal Products will play an 
important role in general risk 
communication
 ￿ ￿ ￿ ￿ The European Agency for the Evaluation 
of the Medicinal Products is undertaking a 
broad risk communication effort with an 
informative and accessible website 
(www.emea.eu.int)
￿  ￿  ￿  ￿ the European Food Safety Authority 
has been established and it will be fully 
operational by the first half of 2003
Member States, 
industry, 
academia, civil 
society, EFSA, 
EMEA, 
Commission
LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan
 (1)
Societal scrutiny and dialogue
2002
onwards
2002
onwards
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13 (c) ￿  ￿  ￿  ￿ the Commission encourage public debates on 
biotechnology between scientists, industry and 
civil society 
Specific measures have been taken by the Commission 
in this regard. In particular:
￿  ￿  ￿  ￿ An advisory group has been established in 2000, 
the European Group on Life Science (EGLS), with a 
mandate that includes promoting and supporting 
science communication/debate strategies involving 
society at large. Under the guidance of the EGLS, the 
Commission is regularly organizing a series of Life 
Sciences Discussion Platforms 
￿  ￿  ￿  ￿ The role of the EGLS, providing examples of 
multistakeholders platforms for the discussion of life 
sciences, should be reinforced through the 
development of systematic mechanisms of exchange 
of good practices, and amplification thereof, between 
Countries and organizers of all kinds.
Member States, 
industry, 
academia, civil 
society, EFSA, 
EMEA, 
Commission
￿ ￿ ￿ ￿ Several projects involving consumers platforms 
and/or other public discussion forums are ongoing 
under the Quality of Life FP5 program 
￿  ￿  ￿  ￿ The creation of a « European network of 
citizens», as a forum for informed reflection on 
biosciences issues, should be a final goal of on-going 
pilot initiatives.
￿ ￿ ￿ ￿ Initiatives of public perception monitoring have been 
regularly supported, starting from FP4
￿  ￿  ￿  ￿ Furthermore, the planned European web-portal 
and the Commission's web-site that should provide a 
broad entry platform into the Commission's work on 
biotechnology (see Action 8), should present an 
improved opportunity for stakeholders and citizens to 
express their views.
￿  ￿  ￿  ￿  in the context of the creation of the European 
Research Area, the Science and Society Action Plan is 
also developing a number of actions directly beneficial 
to the life science and biotechnology issues.
2002
onwards
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LIFE SCIENCES AND BIOTECHNOLOGY - A STRATEGY FOR EUROPE
State of implementation of action plan
 (1)
Developing life sciences and biotechnologies in harmony with ethical values and societal goals
14 The Commission will 
￿  ￿  ￿  ￿ strengthen and focus Community support for 
research into socio-economic and ethical issues 
and dissemination of results, including criteria for 
assessing the benefits of using biotechnology in agri-
food production, to facilitate future reporting and to 
provide a good basis for societal decisions on the 
application of biotechnology and life sciences.
￿  ￿  ￿  ￿ program research support to a more systematic 
mapping of benefits and disadvantages/risks 
which should include a strong component for 
dissemination of information and debate.
￿  ￿  ￿  ￿ ensure that ethical, legal and social 
implications are taken into account at the earliest 
possible stages of Community supported research 
by means of funding bioethics research and of 
providing an ethical review of research proposals 
received. 
￿  ￿  ￿  ￿ The specific program “Quality of Life and 
Management of Living Resources “ under the Fifth 
Framework Research Program (1998-2002) has so far 
ensured that the  ethical dimension of research in  Life 
Sciences and Biotechnology is addressed by:
￿  ￿  ￿  ￿ Supporting  research in Bioethics, which has 
allowed to analyze the ethical issues linked to 
biotechnology and to  better understand the  ethical 
and cultural divergences in Europe, to develop 
proposals for codes of  conduct as well as to  establish 
a database in bioethics;
￿  ￿  ￿  ￿ Fostering ethical awareness in research, an 
obligation is put on the applicants to describe the 
potential ethical aspects of the proposed research 
regarding its objectives, the methodology and the 
possible implications of the results, and to justify the 
research design. An ethical assessment takes place 
for all proposals during the scientific evaluation and a 
specific ethical review has been implemented for 
proposals dealing with sensitive issues;
￿  ￿  ￿  ￿ The policy developed under the Fifth Framework 
Program  will be reinforced in the Sixth Framework 
Program for Research (FP6) by
￿  ￿  ￿  ￿ Promoting the integration of the analyses of the 
ethical, legal and social spects into research projects: 
research in bioethics will be an integrated part of 
research projects in relation to  the thematic priorities 1  
“ Life Sciences, genomics and biotechnology for 
health” and 5. “Food quality and safety” 
￿ ￿ ￿ ￿ Encouraging public dialogue and participation of 
stakeholders in research projects
￿ ￿ ￿ ￿ Fostering ethical awareness and foresight 
attention in research
￿ ￿ ￿ ￿ Supporting specific actions to promote the debate 
on ethical, legal, social and wider cultural aspects 
of life Sciences and Biotechnology
Commission
￿  ￿  ￿  ￿ Improving the awareness of scientists. To this 
end a study on national, international and 
professional training material for ethics in research 
was launched in 2002; such material will be largely 
disseminated; Furthermore, a study on training 
programmes in ethics in research established in 
scientific faculties across Europe has been launched. 
Those programmes will be connected across Europe.
￿  ￿  ￿  ￿ Addressing via the specific programme "Structuring 
the ERA3 cross-cutting questions through comparative 
research, foresight and impact studies on ethical 
issues in relation to sciences and technological 
developments.
￿  ￿  ￿  ￿ Following the Council conclusion on the five 
specific programs implementing FP6, the Commission 
will publish a report on the evolution of stem cells 
research and will organize a public institutional 
seminar on the subject by Spring 2003. 
2002-06
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State of im plem entation of action plan
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15 The Commission will
￿  ￿  ￿  ￿ propose to enhance the role of the 
European Group on Ethics
￿  ￿  ￿  ￿ The role of the European Group of 
Ethics (EGE) has been enhanced by 
establishing closer collaboration with 
Commission services, and by increasing 
exchanges with other institutions namely 
with EP (e.g., participation of MEP to the 
round tables organized by the Group, 
hearing of the Group by the EP temporary 
commission on genetics, etc…).
￿  ￿  ￿  ￿ Following the EP resolution of the 
Commission strategy on life sciences and 
biotechnology, the Commission intends to 
propose a modification of the mandate of 
the EGE to allow the EP and Council to be 
involved in the nomination of the members 
of the group.
ethical bodies, 
legislatures, 
Commission
￿ ￿ ￿ ￿ launch a separate consultation of the 
other Community institutions on possible 
structural and procedural improvements
￿  ￿  ￿  ￿ The Group is involved in the ongoing 
discussion on how to integrate ethical 
consideration in decision making process 
within EU, which also implies to carry out an 
in depth reflection on the evolution of its role 
(e.g., participation of EGE to the workshop 
within the framework of the Danish Action 
Plan for Biotechnology and Ethics).
￿  ￿  ￿  ￿ The EGE will actively participate to the 
public institutional seminar on bioethics to 
be organized by the Commission following 
the Council conclusion regarding the 
specific programs of the FP6 (see action 
14). 
￿  ￿  ￿  ￿ promote collaboration between 
Community, national and local levels by 
promoting networking of national and 
local ethical bodies and elected 
representatives
￿  ￿  ￿  ￿ Contacts and exchanges between the 
EGE and the national instances of ethics 
are regular and facilitated by the fact that 
several EGE members also are members of 
such national instances. Furthermore, the 
Group systematically meets every six 
months the national instances of the 
Member States in charge of the presidency 
￿  ￿  ￿  ￿ The EGE will create a News Letter on 
the activities carried out by national ethics 
instances; such regular publication will 
improve the diffusion of informations and 
facilitate contacts and collaboration between 
ethics committees. Furthermore, in view of 
the preparation of its future opinion of 
genetic testing in the work place, the EGE 
￿ ￿ ￿ ￿ organize a network of academic and 
professional experts for ad-hoc advice on 
specific socio-economic aspects.
￿ ￿ ￿ ￿ Networks of academics and experts have 
been set up by the Commission to address 
socio-economic aspects of biotechnology, 
as the European Group on Life Sciences 
set up in April 2000,  to meet the need of 
high level advice on Life Sciences and 
Biotechnology.
2002
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State of implementation of action plan
 (1)
16 The Commission
￿ will develop, jointly with the European 
Parliament, outreach measures to inform 
about the analysis of ethical issues at the 
EU level. 
￿ ￿ ￿ ￿ The opinions issued by the European 
Group on Ethics in Science and New
Technologies play a relevant role in the ethical
debate at European level. 
￿ ￿ ￿ ￿ A web-site is currently under construction to
promote the dissemination of the results of
multidisciplinary research projects into the
ethics of life science and biotechnology funded
and coordinated under FP5, and to contribute to
inform the ethical debate.
￿ ￿ ￿ ￿ In 2002 a workshop was organised with
existing networks in the field of "ethics in
research" to explore the possibility to create a
"European Information and Documentation
system on ethics in science", in order to
improve the generla access to regulation and
ethical debates in the EU. A feasibility study is
expected.
￿  ￿  ￿  ￿ The participation of all stakeholders in 
research projects under Sixth Framework 
Program, in particular under the thematic 
priorities 1. “ Life Sciences, genomics and 
biotechnology for health” and 5. “Food quality 
and safety” will be encouraged in order to 
engage in an interactive dialogue between 
scientists, physicians, industry, patients, 
consumers, farmers, animal welfare 
organizations, ethicists, lawyers and the public 
at large – for socially responsible choices, 
shared understanding and greater public 
participation. 
European 
Parliament, Member 
States, regions, 
industry, 
institutions, 
Commission
￿ ￿ ￿ ￿ will work with public and private partners, to 
identify areas where it is possible to establish 
consensus on ethical guidelines/standards or 
best practice. Areas might include stem cell 
research, biobanks, xenotransplantation, 
genetic testing and use of animals in 
research. Such guidelines could, when 
appropriate, take the form of self-regulatory 
initiatives in the scientific community and 
industry.
￿ ￿ ￿ ￿ The Commission has during the last 12
months conducted 3 surveys regarding national
legislations in relation to xenotransplantation,
human embryonic stem cell research and
biobanks. These surveys allows to analyze best
practice and provide a first step towards
preparations of guidelines. 
￿ The opinions of the EGE and the work in
Council of Europe are other important
documents in this respect.
￿  ￿  ￿  ￿ Transnational, multidisciplinary and 
pluralistic focus groups may be established in a 
first step to develop guidelines for research 
funded under FP 6 regarding areas such as 
animal experimentation biobanks, 
xenotransplantation, genetic testing and human  
stem cell research. 
2002
onwards
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State of implementation of action plan
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17 ￿  ￿  ￿  ￿ to develop research and pilot projects 
to clarify the need, and possible options, 
for agronomic and other measures to 
ensure the viability of conventional 
and organic farming and their 
sustainable co-existence with genetically 
modified crops. 
￿  ￿  ￿  ￿  A study on scenarios co-existence 
of GM, conventional and organic crops 
in European agriculture was carried out by 
the Commission. It provided the first results 
on this issue.  
￿ ￿ ￿ ￿ A strategy paper is under development
￿ ￿ ￿ ￿ The following actions are envisaged
for the elaboration and implementation of
the strategy: 
￿ ￿ ￿ ￿ follow-up of the study on co-existence
planned for 2003, aiming to confirm and to
enlarge the preliminary first results of the
study
￿ ￿ ￿ ￿ round table on co-existence to be
organized in April 2003
￿ ￿ ￿ ￿ future studies and research within the
FP6
Member States, 
professional 
associations, 
other operators, 
Commission
￿  ￿  ￿  ￿ To launch a new action program for 
the conservation, characterization, 
collection and utilization of genetic 
resources in agriculture in the 
Community.
￿ ￿ ￿ ￿ A proposal for a Regulation on the
conservation, characterization, collection
and utilization of genetic resources the
proposal of a new regulation is in
preparation
Demand-drive applications through informed choice
2002
onwards
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State of implementation of action plan
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18 ￿ ￿ ￿ ￿ to speed up the adoption of the three 
legislative proposals, revising the
Community pharmaceutical legislation
￿  ￿  ￿  ￿ The review consists of 3 proposals, i.e. 
one regulation dealing with the centralized 
procedure and two directives modifying the 
existing codes in the field of human and 
veterinary medicinal  
products(COM(2001)404 Final), which were 
adopted by the Commission on 26.11.2001
￿  ￿  ￿  ￿ The EP concluded its first reading on 2 
October 2002
￿  ￿  ￿  ￿ Discussion in the Council is 
progressing slowly.
￿  ￿  ￿  ￿ A political agreement is expected to 
be reached under the Greek Presidency.
  European 
Parliament, 
Council
19  ￿ ￿ ￿ ￿ To speed up the adoption of the two
following legislative proposals:
￿ ￿ ￿ ￿ Proposal for a European Parliament
and Council Regulation on Traceability 
and Labeling of Genetically Modified
Organisms and Traceability of Food
and Feed derived from Genetically
Modified Organisms.
￿  ￿  ￿  ￿ The European Parliament completed 
its first reading on 3 July. 
￿  ￿  ￿  ￿  The Environmental Council reached a 
political agreement on 9 December.
European 
Parliament, 
Council
￿ ￿ ￿ ￿ Proposal for a European Parliament
and Council Regulation on Genetically 
Modified Food and Feed.
￿  ￿  ￿  ￿ The European Parliament completed 
its first reading on 3 July.
￿  ￿  ￿  ￿  The Agriculture Council reached a 
political agreement on 28 November.
Short-term regulatory action
Pharmaceutical legislation
2002
2002
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20 ￿ ￿ ￿ ￿ To finalize the legislative proposals
which have already been announced,
such as initiatives concerning GM plant
propagating material, environmental 
liability and the implementation of the
biosafety protocol. 
The Commission has adopted 
 
￿  ￿  ￿  ￿  a Proposal concerning the 
environmental liability (COM(2002)17 final 
of 23 January 2002).
 
￿  ￿  ￿  ￿  a Proposal for a Regulation of the 
European Parliament and the Council on the 
transboundary movements of GMOs 
￿  ￿  ￿  ￿ Both proposals on the environmental 
liability and on the implementation of the 
Biosafety Protocol are under examination by 
other Community Institutions. 
European 
Parliament, 
Council, 
Commission
￿  ￿  ￿  ￿  a Proposal for a Council Decision or 
the conclusion of the Biosafety Protocol 
on the behalf of the European Community 
(COM(2002)127 final), which was adopted 
by the Environment Council of 25 June 2002
￿  ￿  ￿  ￿ On 27 August 2002 the European 
Community deposited its instrument of 
ratification to the Secretary General of the 
United Nations in New York
￿  ￿  ￿  ￿ The proposal for establishing 
thresholds for the adventitious presence 
of GMOs in conventional seeds is to be 
finalized in the light of the developments on 
the proposals on food/feed and traceability.
￿ ￿ ￿ ￿ the proposal for including the 
environmental risk assessment of seeds 
in the seeds legislation will be considered 
once the discussions on the proposals on 
GM food/feed and traceability are finalized 
and at the latest in the context of the report 
to Council and EP on the feasibility to 
improve further the consistency and 
efficiency of the framework for authorizing 
GMOs (see action 22).   
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State of im plem entation of action plan
 (1)
21 ￿ ￿ ￿ ￿ To ensure that legislation is enforced in a
uniform and effective way across the
Community and to adopt appropriate 
implementing measures required under
relevant legislation, including the necessary
guidance for detection and sampling
methodology
In order to ensure uniform and effective 
enforcement of EC legislation,
￿   ￿   ￿   ￿   four implementing measures  have been 
adopted
1) Council Decision 2002/813/EC establishing the 
Summary Notification Information Format Part 
B(OJ, L280) 
2) Council Decision 2002/812/EC establishing the 
Summary Notification Information Format Part C 
(OJ L280) 
3) Commission Decision 2002/623/EC 
establishing guidance notes supplementing 
Annex II to Directive 2001/18/EC (OJ L200), 
4) Council Decision 2002/811/EC establishing the 
guidance notes supplementing Annex VII to 
Directive 2001/18/EC (OJ L280)
￿  ￿  ￿  ￿ The Commission is considering other 
implementing measures required by Directive 
2001/18/EC
￿  ￿  ￿  ￿ The proposal for GM Food/Feed foresees 
the JRC to become Community Reference 
laboratory to be assisted by the “European 
Network of GMO laboratories
￿  ￿  ￿  ￿ A proposal for a Commission Regulation on 
a protocol for sampling and testing of seed 
lots of non-GM varieties for the presence of GM 
seed will be put forward together with a proposal 
for a Commission Directive amending the 
annexes of the different seed Directives, setting 
additional conditions and requirements 
concerning the adventitious or technically 
unavoidable presence of GM seeds in seed lots 
of non-GM varieties
Commission
￿ ￿ ￿ ￿  the JRC of the Commission continues to co-
ordinate a network of laboratories responsible 
for GMO testing from Member States and third 
countries. The main objective of this network is 
to contribute effectively to the European 
harmonization and standardization of means and 
methods for sampling, detection, identification 
and quantification of GMOs and GM products. 
The JRC is also providing certified reference 
materials.
￿ ￿ ￿ ￿ To establish a molecular register that is
accessible to the public, containing
information on events of genetic modification.
￿  ￿  ￿  ￿ The creation of a molecular register of 
known GMO molecular and biological data has 
begun 
Implementation and enforcement activities
2002-03
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 (1)
Specific long term regulatory action
22 ￿  ￿  ￿  ￿ To report on the feasibility of options 
to improve further the consistency and 
efficiency of the framework for 
authorizing GMO’s for deliberate 
release into the environment, including 
a centralized Community authorization 
procedure.
￿  ￿  ￿  ￿ A call for tender for a study  is being 
launched.
￿  ￿  ￿  ￿ This study is aimed at preparing the 
Commission's report to the other EU 
institutions.
Commission
23 ￿  ￿  ￿  ￿ To support the development of 
methodologies for monitoring potential 
long-term environmental impacts of 
GMO’s as compared with conventional 
crops, and methodologies for the 
monitoring of effects of genetically 
modified food and feed as compared 
with conventional food and feed. With 
the establishment of the European Food 
Safety Authority, the work on the early 
identification of emerging risks will be 
reinforced and upgraded.
￿ a study for the development of specific
sets of monitoring criteria for individual
groups of GMOs and for different transgenic
phenotypes has been envisaged for end 
2003/mid 2004
￿  ￿  ￿  ￿ Short and medium term actions 
concerning the development of 
methodologies for post-marketing will be 
developed in consultation with European 
Food Safety Authority by 2003
￿ ￿ ￿ ￿ Council Decision 2002/811/EC (see 
action 21) will contribute to monitor potential 
long-term environmental impacts of GMOs.
Commission
2003
2002
onwards
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24 ￿  ￿  ￿  ￿ The Commission should continue to play a 
leading role in developing international 
guidelines, standards and recommendations in 
relevant sectors, based on international scientific 
consensus and, in particular, push for the 
development of a consistent, science-based, 
focused, transparent, inclusive and integrated 
international system dealing with food safety issues.
￿  ￿  ￿  ￿ In the G8, the Commission has over the last two 
years actively pushed for a consistent, science-based, 
focused, transparent, inclusive and integrated 
international system dealing with food safety issues. 
￿  ￿  ￿  ￿ The Commission continues to play a leading role 
in Codex Alimentarius, OECD and under the 
biosafety protocol  with a view to develop 
international guidelines, standards and 
recommendations on food safety and biotech issues.
￿  ￿  ￿  ￿ After 11 September 2001, the G8 has been 
preoccupied with combating terrorism and the issue of 
food safety and, as a consequence, biotechnology has 
not been on their agenda.
Commission
25 (a) ￿  ￿  ￿  ￿ the Commission will in cooperation with 
Member States support the redefining of national 
research towards an appropriate mix of 
traditional techniques and new technologies, 
based on priorities developed with local farmers. 
￿  ￿  ￿  ￿ This action is addressed in the Commission 
Agricultural Research for Development (ARD) 
strategy document, elaborated in close collaboration 
with the Member States, available at the following 
address: http://europa.eu.int/comm/development/rurpol
￿ ￿ ￿ ￿ A meeting with other donors (World Bank, FAO, 
USAID, IFAD, African Development Bank, EU Member 
States), African Sub-Regional Organizations , Forum 
Africain pour la Recherche Agronomique and Global 
Forum on Agricultural Research  took place on 24-26 
June 2002, on Competitive Funds, providing for 
concrete recommendations
￿  ￿  ￿  ￿ On 30-31 January 2003, the Commission 
organized a Life Sciences Discussion Platform: 
Towards sustainable Agriculture for Developing 
Countries, aiming to address the potential, benefit and 
risks of life sciences and biotechnology for sustainable 
agriculture in developing countries
￿  ￿  ￿  ￿ Implementation of this approach through the Sub 
Regional Organizations SADC / SACCAR program is 
under preparation (estimated amount: 15M￿) with the 
participation of the Member States through European 
Initiative for Agriculture Research for Development
￿  ￿  ￿  ￿ A program is under preparation with NGOs, 
farmers associations, private sector, extension 
services, etc., through Global Forum on Agricultural 
Research, aiming at supporting the participation of all 
stakeholders at all stages of Agricultural Research for 
Development  in ACP countries. Its expected starting 
date is beginning of 2003.
Member States, 
Commission
A European agenda for international collaboration
Europe's responsibilities towards the developing countries     Agriculture
2002
onwards
2002
onwards
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25 (b) ￿ ￿ ￿ ￿ the Commission will in cooperation
with Member States support the 
establishment of effective research
partnerships between public and private
research organizations in developing
countries and in the EU, and the
adequate capacity and infrastructure
for developing countries to enter into
such partnerships, in accordance with
international commitments under the
Conventions.
￿  ￿  ￿  ￿ Partnerships, capacity building and 
physical infrastructures are being provided 
through various financial instruments, such 
as on-going Commission research support 
projects and ARD programs. The FP6 will 
pursue these efforts, particularly through its 
international dimension.
￿ ￿ ￿ ￿ South-South and South-North 
Partnerships will be strengthen through the
implementation of Competitive Funds at
national level, subregional level (see action
25a), regional level (FARA, FONTAGRO,
etc.), and at global level (GFAR, CGIAR
challenge programs). 
Member States, 
Commission
25 (c) ￿  ￿  ￿  ￿ the Commission will in cooperation 
with Member States support sub-
regional, regional and international 
organizations, in particular the 
International Agricultural Research 
Centers.
￿  ￿  ￿  ￿ The Commission and the Member 
States are working together through 
European Initiative for Agricultural 
Research for Development (EIARD)  to 
elaborate common positions on and 
participation in the Consultative Group On 
international Agricultural Research 
(CGIAR) policy, governance and 
management structures, as well as to co-
ordinate respective supports.
￿  ￿  ￿  ￿ The proposed EC support to the  
CGIAR for the period 2002-2004 has been 
endorsed by the EU Member States in the 
Foods Aid / Food Security Committee at the 
end of May 2002 and will amount to 22 M￿ 
per year.
￿  ￿  ￿  ￿ Regular participation of the Commission 
in the European Initiative for Agriculture 
Research for Development (EIARD) 
meetings is ensured.
￿ ￿ ￿ ￿ Annual contracts will be prepared and 
signed by the Commission with the 
Consultative Group On international 
Agricultural Research (CGIAR) 
Secretariat / World Bank for the 
mobilization of the EC support 2002-04. 
￿ ￿ ￿ ￿ Priority areas of EC support and 
implementation modalities are detailed in  
EC strategy document "GCRAI: éléments 
de stratégie" available on Commission 
website
￿  ￿  ￿  ￿  The modalities to select the CGIAR 
projects that will be supported by the EC 
have been reviewed with the EU Member 
States in October 2002, as well as the lists 
of projects to be financed in 2003.
Member States, 
Commission
2002
onwards
2002
onwards
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Europe's responsibilities towards the developing countries      Genetic resources
26 (a) The Commission and the Member States 
will support the conservation and 
sustainable use of genetic resources in 
developing countries and their equitable 
sharing of benefits arising from their use 
by:
￿  ￿  ￿  ￿ supporting the development and 
enforcement of effective measures to 
conserve, to use sustainably and to 
provide access to genetic resources 
and traditional knowledge, as well as to 
share equitably the benefit arising from 
them, including income generated by 
intellectual property protection. Support for 
local communities is vital to conserve 
indigenous knowledge and genetic 
resources.
￿  ￿  ￿  ￿ At the WTO : Commission actively 
participated in review of Article 27.3(b) of 
the Trade Related Intellectual Property 
(TRIPs) Agreement and, in the context of 
the DDA, in the working program mandated 
by para. 19 of the Doha Ministerial 
declaration. A Communication on these 
issues, which was submitted by the 
Commission to the TRIPs Council on 16 
September 2002 (ref. IP/C/W/383), was 
welcomed by several deveoping countries 
as a useful contribution
￿  ￿  ￿  ￿ At the CBD : the Commission was an 
active participant in several expert and 
working groups which prepared the Bonn 
Guidelines on Access to Genetic 
Resources and Benefit-sharing adopted 
at the 6th Conference of the Parties in The 
Hague on 19 April 2002
￿  ￿  ￿  ￿ The Commission will continue its active 
participation in the debate on TRIPS and 
Biodiversity in the WTO.
Member States, 
Commission
￿  ￿  ￿  ￿ At the FAO : Commission and Member 
States played key role in the adoption of the 
International Treaty on Plant Genetic 
Resources and provides input to the 
current dialogue on the conditions for ABFS 
in the context of the IT with an aim to agree 
on a standard Material Transfer 
Agreement.
2002
onwards
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26 (b) ￿  ￿  ￿  ￿ supporting the participation of 
delegates from developing countries 
in the negotiations of relevant 
International Conventions. 
￿  ￿  ￿  ￿ Financial resources are available in 
the envelope "Intra-ACP resources 9th 
European Development Fund (EDF 9) to 
contribute to this objective. 
￿ ￿ ￿ ￿ A Commission Interservice Steering 
group on issues related to the WTO-
Sanitary and Phytosanitary Agreement 
(SPS) has been created to co-ordinate 
actions and financial support in this 
objective
Member States, 
Commission
26 (c) ￿  ￿  ￿  ￿ supporting measures to promote 
greater regional co-ordination in 
legislation to minimize disparities in 
access, benefits and also trade in 
products derived from genetic resources, 
in accordance with international 
commitments
￿  ￿  ￿  ￿ A Commission's study "Benefits, 
needs, constraints and 
recommendations for development and 
use of biotechnology in developing 
countries" is under preparation. The 
objective of this study is to list 
recommended standards and guidelines to 
promote the safe and effective development 
and use of green, white and red 
biotechnology in developing countries, 
based on their autonomous choice and on 
their national development strategies. 
Stakeholders will be consulted on the terms 
of reference of the study at the beginning 
of 2003.
￿  ￿  ￿  ￿ Several African sub-regional 
research organizations (e.g. ASARECA, 
SACCAR and CORAF) could be well placed 
to work on these subjects (i.e. national and 
regional policy processes and coherence). 
￿  ￿  ￿  ￿ EC financial resources mobilized  for 
Agricultural Research for Development 
(ARD)  at sub-regional level (respectively 
28, 19 and 20 M￿), in close collaboration 
with the Member States mainly through 
European Initiative for Agricultural Research 
for Development (EIARD), could be partly 
utilized for this purpose 
Member States, 
Commission
2002
onwards
2002
onwards
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(1)
Europe's responsibilities towards the developing countries     Health
27 ￿  ￿  ￿  ￿ The Commission and the Member States 
should work with the international community 
to concretize the commitment to research 
to combat HIV/AIDS, Malaria, TB and other 
main poverty-related diseases and also 
identify effective measures to support 
developing countries in establishing the 
structures needed to deploy a health policy.
￿  ￿  ￿  ￿ Over the last decade the Commission has 
substantially invested in research on Poverty-
Related Diseases. In the 5th Framework 
Program alone more than 110 million ￿ have 
been contributed  to 90  projects on HIV/AIDS, 
malaria and TB. In addition Member States 
invest at national level more than 200 million ￿ 
in research for the development of new 
interventions against these diseases.
Improved co-ordination of research activities 
between Member States will increase the impact 
and efficiency of research efforts. With the 
establishment of the European and Developing 
Countries Clinical Trials Partnership (EDCTP) 
the fragmentation of European research efforts 
can be overcome and also be translated into 
clinical interventions that are applicable in the 
Developing Countries.  
￿  ￿  ￿  ￿ Fifteen European countries, encouraged 
and supported by the European Commission, 
have initiated the establishment of the EDCTP. 
For the initial period of  5 years a contribution of 
200 million ￿ assigned by the 6th Framework 
Program for Research (2002-2006), is requested 
from the Community to serve as a catalyst to 
start the activities of the Joint Program of the 
EDCTP. The Commission will submit a proposal 
to the Council and Parliament to apply Article 
169 of the Treaty to allow  for participation of 
the Community in the EDCTP Joint Program. 
The EDCTP should be operational in early 2003.  
Member States, 
Commission
￿  ￿  ￿  ￿ An international dialogue and training 
courses have been organised, together with the 
National Institute of Health (NIH), aiming to 
assist in capacity building for the ethical 
assessment of research projects and clinical 
trials in developing countries In 2002 and 2003 
workshops have been organised Seoul/South 
Korea and in Mali/Africa. 
￿  ￿  ￿  ￿ Further workshops are planned in Egypt and 
Uganda.
￿  ￿  ￿  ￿ The Program for Action against AIDS, 
malaria and tuberculosis has progressed on 
the main issues of impact, affordability and 
research.
￿  ￿  ￿  ￿ The Commission will present its progress 
report to the EP and Council beginning 2003. 
Progress will be monitored by the annual and 
mid-term country reviews and by periodic 
meetings of the interservice group on the 
progress of the program for Action.
2002
onwards
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(1)
 
28
(a),(b),(c),(e)
 
To support:
￿  ￿  ￿  ￿ the safe and effective use of 
modern biotechnologies in developing 
countries, based on their autonomous 
choice and on their national development 
strategies.
￿  ￿  ￿  ￿ measures to increase the capacity 
of developing countries to assess and 
manage risk for man and the 
environment, under conditions prevailing 
in the country.
￿  ￿  ￿  ￿ the development of appropriate 
administrative, legislative and regulatory 
measures in the developing countries, for 
the proper implementation of the 
Cartagena Protocol.
￿  ￿  ￿  ￿ that the international regulatory 
requirements remain manageable by 
developing countries, so as not to impede 
their trade and production prospects.
￿  ￿  ￿  ￿ A Commission's study "Benefits, 
needs, constraints and 
recommendations for development and 
use of biotechnology in developing 
countries" is under preparation. (See 
action 26c) 
Commission
28 (d) ￿  ￿  ￿  ￿ that international research on 
social, economical and environmental 
impacts are effectively adapted to take 
into account conditions prevailing in 
developing countries and that the findings 
are subsequently disseminated to them in 
an appropriate format.
￿  ￿  ￿  ￿ Impact monitoring and subsequent 
recommendations are fully integrated in the 
EC supported research programs, being 
at national, sub-regional, regional and global 
levels
Commission
Europe's responsibilities towards the developing countries   Responsible and careful use
2002
onwards
2002
onwards
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(1)
29 (a)
The Commission will enhance:
￿  ￿  ￿  ￿  the general foresight function across 
Commission services, and in particular its role 
in technology foresight through its Institute for 
Prospective Technological Studies (IPTS), for 
early identification of newly emerging issues 
and of elements of a policy response 
￿ ￿ ￿ ￿  The Commission's Joint Research Center 
(JRC), to which IPTS belongs, has enlarged 
foresight activity in its multiannual work 
program (MAWP, 2003-2006). One of the 
MAW P's four priorities focus explicitly on 
biotechnology and includes the biotechnology 
foresight exercise BIOFOR. The first round of 
BIOFOR is scheduled to start in the second half 
of 2003, with completion and dissemination of 
results by the end of 2004.
￿  Other IPTS foresight and anticipation 
studies in certain biotechnology applications 
(namely in genetic testing of humans, on tissue 
engineering, on the use of GMOs in agriculture, 
etc.) are on going and will feed into BIOFOR.
 ￿   ￿   ￿   ￿   A study on genetic engineering in 
aquaculture will be funded in 2003.
￿ ￿ ￿ ￿   starting point will be biotechnology 
development as enabling technology. The 
following application sectors might be included: 
￿  Human and animal health (e.g. drug 
discovery, pharmacogenomics, envirogenomics, 
diagnosis, tissue and organ engineering),
￿ Agriculture and food production, nutraceutical 
production sector and personal nutrition 
(nutrigenomics),
￿ Fisheries and aquaculture. 
￿ Environmental applications and 
bioremediation,
￿  New industrial processes and substitution 
processes,
￿ Applications in security and defense,
￿ Horizontal developments: in-silico 
biotechnology; bioinformatics, data management 
and protection.
Commission, 
Member States
29 (b) ￿  ￿  ￿  ￿  its monitoring and review function to 
assess
- the relevance, coherence and effectiveness 
of legislation and policy
- the extent to which policy objectives are 
achieved and legislation enforced 
- the societal and economic impact of 
legislation and policy measures
In pursuit of these objectives and to further 
strengthen policy coherence, the Commission 
￿   ￿   ￿   ￿   In 1991, a single inter-departmental co-
ordination body, the Biotechnology Co-
ordination Committee (BCC), was established 
in order to ensure the continuos co-ordination 
between Commission services and the 
monitoring and review function of the 
Commission in this area. The BCC comprises all 
services with an interest in biotechnology and 
consists of high-level officials from those 
Commission services. 
￿   ￿   ￿   ￿   Furthermore, for the preparation of the 
Commission strategy on Life Sciences and 
Biotechnology and in order to monitor the 
implementation of such a strategy, a 
Commission Steering Committee consisting of 
the most directly involved cabinets and services 
has been set up and has met regularly since 
2001. 
Commission, 
Member States
Implementation and coherence across policies, sectors and actions
2002 
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29 (c ) ￿  ￿  ￿  ￿ will reinforce continuous co-ordination 
between its services and calls upon 
Member States to also provide enhanced 
foresight/review functions and a 
coordinated interface for a dialogue on 
these issues.
￿  ￿  ￿  ￿ A reflection is on how internal 
Commission co-ordination on biotechnology 
could and should be enhanced is ongoing. 
Results are expected by  mid 2003
Commission, 
Member States
30 ￿  ￿  ￿  ￿ The Commission will present a 
regular Report on Life Sciences and 
Biotechnology to monitor progress and 
indicate possible specific proposals to 
ensure policy and legislative coherence. 
The report will draw on the conclusions 
under actions 10 and 29.
￿  ￿  ￿  ￿ The current report is the document 
referred to by this action. 
￿  ￿  ￿  ￿ In its conclusions, the European 
Council in Barcelona asked Council and 
the Commission to develop the detailed 
measures to implement the approach 
proposed and report on progress in good 
time for the 2003 Spring European Council. 
Commission
2003
onwards
2002
onwards
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